A Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 14 Jun 2008 Results were presented at the Annual European Congress of Rheumatology meeting in 2008.
- 14 Jun 2008 Results were presented at the 2008 Annual European Congress of Rheumatology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History